Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

2002255 citationsJournal Article

Authors

The PG combination is as equally active and well tolerated as the PC combination in patients with advanced NSCLC.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 20, Issue 17, pp. 3578-3585

Field-Weighted Citation Impact: 24.30